The NEC baby formula lawsuit landscape has shifted dramatically throughout 2026, and further changes are still unfolding. On April 9, 2026, a Cook County jury handed four families a combined $70 million verdict against Abbott Laboratories — the third major plaintiff victory in state court and the first multi-family Illinois trial in this litigation’s history. Now, with approximately 1,700 lawsuits involving claims on behalf of about 12,700 children still pending in state and federal courts, and Abbott reaching a sweeping $670 million settlement in August 2026, the litigation is entering a pivotal new phase. The federal docket reached its own inflection point when Inman v. Mead Johnson, the first Enfamil bellwether case to go to trial in federal court, ended in a unanimous defense verdict on August 31, 2026. With verdicts paid out to plaintiffs totaling more than $555 million, a Bloomberg Intelligence estimate placing total liability at $3 billion, and the Illinois Fifth District Appellate Court overturning a $60 million Mead Johnson verdict in June 2026, families and legal observers are watching every courtroom closely. Here is everything you need to understand about where this litigation stands — and where it is headed.
The April 9 Cook County Verdict: What the $70M Win Means
The Cook County verdict was a milestone on multiple fronts. Four families whose premature infants developed necrotizing enterocolitis (NEC) — a severe, life-threatening gastrointestinal disease that destroys intestinal tissue primarily in preterm babies — pursued their claims together in the first consolidated multi-family NEC trial in Illinois state court. The jury awarded $53 million in compensatory damages and an additional $17 million in punitive damages, totaling $70 million. All four infants survived, but three required surgery and all suffered severe, lasting complications after being fed Abbott’s Similac Special Care 24 in Chicago-area NICUs.
The punitive damages component is particularly significant. The court permitted punitive damages after finding evidence that Abbott may have concealed the NEC risks associated with Similac Special Care 24 from parents and NICU providers. That finding echoes the core allegation running through every NEC baby formula lawsuit filed across the country: that Abbott and Mead Johnson knew cow’s milk-based premature infant formula significantly elevated NEC risk compared to human breast milk fortifiers, yet failed to provide adequate warnings. If you are assessing the potential value of a defective product injury claim involving a NICU infant, a medical malpractice calculator can help you model the range of compensatory and punitive outcomes based on injury severity and jurisdiction.
Abbott maintains that the FDA has found no conclusive evidence linking its formula to NEC and points to independent research in its defense. The company signaled it would appeal the Cook County verdict, consistent with its posture following earlier adverse state-court rulings — though its August 2026 global settlement agreement ultimately changed the calculus for many of those pending appeals.
The Federal Docket: Defense Wins, a Turning Point, and the Inman Verdict
Understanding the arc of the federal litigation requires understanding what came before the August 2026 bellwether trial. MDL 3026 — formally In re Abbott Laboratories et al., Preterm Infant Nutrition Products Liability Litigation — is consolidated in the Northern District of Illinois before Judge Rebecca Pallmeyer. As of November 2026, the MDL contains 847 pending Enfamil and Similac lawsuits, a figure that reflects both new filings and the significant volume of claims being resolved through Abbott’s settlement program.
Earlier in the litigation, defendants scored a series of defense wins at the summary judgment stage in federal court, with Judge Pallmeyer dismissing several bellwether cases on federal preemption and causation grounds. That streak made Inman v. Mead Johnson all the more consequential when it survived summary judgment in May 2026 — the first Enfamil case to clear that hurdle and advance to a federal jury. Plaintiff advocates viewed the case as a critical test of whether families could win in federal court after repeated early dismissals.
The answer, at least in Inman, was no. On August 31, 2026, a federal jury returned a unanimous defense verdict for Mead Johnson, handing the company its first bellwether trial win in the MDL. The defense argued successfully that the scientific evidence did not establish that Enfamil caused the specific infant’s NEC diagnosis, and that Mead Johnson’s warnings were legally adequate. The verdict was a significant setback for plaintiffs in the federal docket and reinforced the view that federal preemption and causation standards present meaningful obstacles that state-court plaintiffs have not faced to the same degree.
Despite the Inman defense verdict, the MDL is far from over. With 847 cases still pending and additional bellwether trials expected to be scheduled, plaintiffs’ attorneys are studying the Inman record carefully to refine their causation evidence and expert testimony for future federal trials. The divergence between state-court plaintiff verdicts and federal defense outcomes is now one of the defining features of this litigation.
State-Court Scoreboard: $555M+ in Verdicts and a New Trial Bombshell
While the federal docket has favored defendants, state courts have been a dramatically different story — though not without setbacks for plaintiffs. Across Illinois and other jurisdictions, juries have returned a string of multimillion-dollar plaintiff verdicts that collectively exceed $555 million. Those figures include the landmark $495 million Gill verdict, which stood as the largest single award in this litigation before Abbott moved to resolve it as part of its August 2026 global settlement.
The state-court landscape was complicated in June 2026 when the Illinois Fifth District Appellate Court overturned a $60 million Mead Johnson verdict and ordered a new trial. The appeals court’s ruling did not exonerate Mead Johnson on the merits; rather, it identified legal errors in how the trial was conducted and concluded that a fresh jury needed to evaluate the evidence. For plaintiffs’ attorneys, the ruling was a reminder that even large state-court wins are not guaranteed to survive appellate scrutiny. For Mead Johnson, it was a meaningful procedural victory, though the underlying claims against the company remain very much alive as the case heads toward retrial.
The overall state-court picture nonetheless remains favorable to plaintiffs. Multiple Cook County juries have now found against Abbott and, in separate trials, against Mead Johnson. Punitive damages have been awarded in several cases. The pattern of verdicts — even accounting for the overturned $60 million award — has sustained the settlement pressure that drove Abbott’s August 2026 agreement and continues to bear on Mead Johnson as it faces ongoing state-court exposure.
What Comes Next: Abbott’s $670M Settlement and the Road Ahead
The most significant development of 2026 came in August, when Abbott reached a $670 million global settlement covering the $495 million Gill verdict and approximately 2,000 additional infant claims. The agreement represents a watershed moment for the litigation: it is by far the largest financial resolution to date and signals that Abbott has concluded that continued trial exposure — particularly in state court — poses unacceptable financial and reputational risk. The settlement does not constitute an admission of liability, and Abbott continues to maintain that its products did not cause NEC.
For the roughly 2,000 families whose claims are covered by Abbott’s agreement, the settlement brings long-awaited resolution. For the many families whose claims are not yet resolved, it sends an important signal about the litigation’s trajectory. With approximately 1,700 lawsuits involving claims on behalf of about 12,700 children still pending against Abbott and Mead Johnson in state and federal courts as of late 2026, the question now is whether Mead Johnson will follow Abbott toward a broader resolution — or continue to litigate aggressively, buoyed by its August 2026 federal bellwether win in Inman.
Mead Johnson’s posture suggests the latter, at least for now. The company secured both the first federal defense verdict in this MDL and an appellate court order granting a new trial in the overturned $60 million state-court case. Those results give Mead Johnson’s legal team credible arguments that the litigation is winnable — particularly in federal court — and reduce the immediate pressure to pursue a settlement on terms comparable to Abbott’s. Observers expect Mead Johnson to push for additional bellwether trials in the MDL and to contest the retried state-court case vigorously.
For families who have not yet filed, the litigation’s active status means that claims are still being accepted. Statutes of limitations vary by state, and some jurisdictions apply discovery rules that toll the clock from the date a family reasonably learned of the connection between formula and NEC rather than from the date of injury. Families who believe their premature infant developed NEC after being fed Similac or Enfamil in a NICU should consult with a mass tort attorney promptly to preserve their rights.
Frequently Asked Questions About the NEC Baby Formula Lawsuit
What is the NEC baby formula lawsuit, and who can file one?
The NEC baby formula lawsuit refers to mass tort litigation brought by families of premature infants who developed necrotizing enterocolitis after being fed cow’s milk-based premature infant formula — primarily Abbott’s Similac Special Care products and Mead Johnson’s Enfamil products — in hospital NICUs. NEC is a devastating gastrointestinal disease that can destroy intestinal tissue, require emergency surgery, and prove fatal. Research published over the past two decades has consistently shown that premature infants fed cow’s milk-based formula face significantly elevated NEC risk compared to those fed human breast milk or donor milk.
Families who may be eligible to file a claim generally include those whose premature infant was hospitalized in a NICU, was fed Similac or Enfamil formula during that hospitalization, and subsequently developed NEC — regardless of whether the infant survived. Claims can be brought on behalf of infants who died from NEC as well as those who survived but suffered serious complications, including intestinal resection, short bowel syndrome, developmental delays, or long-term feeding difficulties. Eligibility does not depend on whether the family consented to formula feeding; many families allege they were not adequately informed of the NEC risk and therefore could not make a fully informed decision.
What did the April 9, 2026 Cook County verdict decide?
The April 9, 2026 Cook County verdict resolved the claims of four families whose premature infants developed NEC after being fed Abbott’s Similac Special Care 24 in Chicago-area NICUs. The jury found Abbott liable and awarded a combined $70 million — $53 million in compensatory damages and $17 million in punitive damages. It was the first consolidated multi-family NEC trial in Illinois state court history, and the punitive damages award reflected the jury’s finding that Abbott may have concealed NEC risk information from parents and healthcare providers.
The verdict does not bind other cases or other courts, but it carries significant weight as evidence of how Cook County juries evaluate the evidence against Abbott. Combined with earlier large plaintiff verdicts in the same court, the April 9 result contributed to the litigation environment that led Abbott to reach its $670 million global settlement in August 2026.
Why is the Inman v. Mead Johnson case so important?
Inman v. Mead Johnson was the first Enfamil lawsuit in MDL 3026 to survive Mead Johnson’s summary judgment motion and reach a federal jury — making it the most closely watched bellwether trial in the federal docket. Judge Pallmeyer denied Mead Johnson’s motion to dismiss in May 2026, clearing the case for trial, and plaintiffs’ attorneys viewed it as their best opportunity to demonstrate that families could prevail in federal court after a series of earlier federal dismissals.
On August 31, 2026, the jury returned a unanimous defense verdict for Mead Johnson. The outcome is significant for several reasons. It demonstrates that federal preemption arguments and causation standards continue to present serious obstacles for plaintiffs in the MDL. It gives Mead Johnson leverage as it evaluates whether to pursue settlement or continue litigating. And it sets a data point — a defense verdict — that will inform how both sides approach future federal bellwether scheduling and settlement negotiations. Plaintiffs’ attorneys have indicated they will analyze the trial record carefully to strengthen causation evidence in future federal trials.
What is the current total of verdicts in the NEC baby formula lawsuit litigation, and what do they mean for settlement?
As of late 2026, plaintiff verdicts in NEC baby formula lawsuits across state courts exceed $555 million in total awards. That figure includes several landmark Cook County verdicts against Abbott and earlier verdicts against Mead Johnson. However, the picture is not uniformly favorable to plaintiffs: the Illinois Fifth District Appellate Court overturned a $60 million Mead Johnson verdict in June 2026 and ordered a new trial, and the first federal bellwether trial in the MDL resulted in a defense verdict for Mead Johnson in August 2026.
For settlement purposes, the state-court verdict record — particularly the $495 million Gill verdict — was a primary driver of Abbott’s decision to reach a $670 million global settlement in August 2026. That agreement resolved approximately 2,000 claims. Mead Johnson has not announced a comparable global resolution, and its recent litigation successes may reduce its near-term settlement urgency. With approximately 1,700 lawsuits still pending involving claims on behalf of about 12,700 children, the litigation against both companies remains active and the financial stakes remain very high.
How long do NEC baby formula lawsuits take, and is there a settlement yet?
The timeline for individual NEC baby formula lawsuits varies considerably depending on whether a claim is filed in state court, in the federal MDL, or in both. State-court cases in Cook County have moved relatively quickly compared to the federal MDL — the first Cook County trial concluded in 2023, and multiple additional state-court trials have concluded since then. The federal MDL has moved more slowly, with the first bellwether trial not occurring until August 2026, and that trial resulting in a defense verdict for Mead Johnson.
As of late 2026, Abbott has reached a $670 million settlement covering approximately 2,000 claims, including the Gill verdict. That settlement represents the most significant resolution to date, but it does not cover all pending Abbott claims, and Mead Johnson has not announced a global settlement. Families whose claims fall outside Abbott’s current settlement program, and all families with claims against Mead Johnson, should expect their cases to continue through the litigation process. Given the volume of pending claims — approximately 1,700 lawsuits involving about 12,700 children as of late 2026 — and the active trial schedules in both state and federal court, additional resolutions are widely anticipated, but the timing and terms remain uncertain. Families considering filing a claim should act promptly given the variation in statutes of limitations across jurisdictions.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.